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Abstract
Collagen VI myopathies, caused by mutations in the genes encoding collagen type VI (ColVI), represent a clinical
continuum with Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) at each end of the
spectrum, and less well-defined intermediate phenotypes in between. ColVI myopathies also share common
features with other disorders associated with prominent muscle contractures, making differential diagnosis difficult.
This group of disorders, under-recognized for a long time, has aroused much interest over the past decade, with
important advances made in understanding its molecular pathogenesis. Indeed, numerous mutations have now
been reported in the COL6A1, COL6A2 and COL6A3 genes, a large proportion of which are de novo and exert
dominant-negative effects. Genotype-phenotype correlations have also started to emerge, which reflect the various
pathogenic mechanisms at play in these disorders: dominant de novo exon splicing that enables the synthesis and
secretion of mutant tetramers and homozygous nonsense mutations that lead to premature termination of
translation and complete loss of function are associated with early-onset, severe phenotypes. In this review, we
present the current state of diagnosis and research in the field of ColVI myopathies. The past decade has provided
significant advances, with the identification of altered cellular functions in animal models of ColVI myopathies and
in patient samples. In particular, mitochondrial dysfunction and a defect in the autophagic clearance system of
skeletal muscle have recently been reported, thereby opening potential therapeutic avenues.
Review
Collagen VI: an important component of connective
tissues
Collagens are major constituents of the extracellular
matrix (ECM), and are found in most connective tissues.
They provide structural and mechanical stability to tis-
sues, but they also play crucial roles in cell-ECM inter-
actions through various receptors [1]. In particular,
collagen type VI (ColVI), an important component of
skeletal muscle ECM, is involved in maintaining tissue
integrity by providing a structural link between different
constituents of connective-tissue basement membranes
(for example, collagen types I and IV, biglycan, and dec-
orin) and cells [2-15] (Figure 1). In addition to its struc-
tural role, ColVI supports adhesion, spreading and
migration of cells, and cell survival, as discussed later in
this review.
ColVI is a heterotrimeric molecule composed of three
individual a(VI) chains that display a similar structure,
with a triple helical domain characterized by the repeti-
tion of the Gly-X-Y amino acid sequence, flanked by
globular domains homologous to von Willebrand factor
A domains [16,17]. In addition to the well-known a1
(VI), a2(VI) and a3(VI) chains encoded in human by
the COL6A1, COL6A2 (located head-to-tail on chromo-
some 21q22.3), and COL6A3 (on chromosome 2q37)
genes [18], three novel chains, a4(VI), a5(VI) and a6
(VI), have recently been identified [19,20]. These chains
have high structural homology to the a3(VI) chain. In
humans, the COL6A4, COL6A5 and COL6A6 genes are
all located on chromosome 3q22.1, with the COL6A4
gene being split by a chromosome break and thus not
coding for a protein [19-21]. The murine orthologs of
these genes are organized in tandem on chromosome 9
(Col6a4, Col6a5 and Col6a6) and encode the a4(VI), a5
(VI) and a6(VI) chains. The expression pattern of the
three novel chains differs between mice and humans,
and also between fetal and adult tissues [19,20].
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Figure 1 Schematic representation of the collagen type VI (ColVI) intracellular assembly process, and interactions with skeletal muscle
extracellular matrix (ECM) components. Individual a(VI) chains fold through their triple helical domains to form monomers (1:1:1 ratio) in the
endoplasmic reticulum (ER), which further align in an anti-parallel manner as dimers and tetramers that are stabilized by disulfide bonds
between cysteine residues (S = S links). Post-translational modifications (indicated in orange) take place in the ER and Golgi, followed by
secretion of tetramers that align non-covalently end to end, to form beaded microfibrils in the ECM. ColVI interacts with collagenous and non-
collagenous components of the basal lamina and interstitial matrix surrounding muscle fibers.
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Importantly, in the context of ColVI myopathies, the a6
(VI) chain is the only one expressed at high levels in
human skeletal muscle, at higher levels in fetal than
adult tissue [19]. In skin, a detailed analysis of the
expression of the human a5(VI) and a6(VI) chains
revealed that both chains are expressed, albeit differ-
ently, and that they are variably altered in tissues from
patients with mutations in the COL6A1, COL6A2 and
COL6A3 genes [22]. Interestingly, the COL6A5 gene had
previously been reported as associated with atopic der-
matitis under the name COL29A1 [23], but this associa-
tion has recently been questioned [24,25]. The knee
osteoarthritis susceptibility locus DVWA was shown to
correspond to the 5’ part of the split COL6A4 gene [21].
Although largely ubiquitous, the expression of ColVI
seems to be finely regulated in different cell types and
tissues, as shown for the murine Col6a1 gene. The iden-
tification of a transcriptional enhancer located in the 5’-
flanking sequence of the gene points to a collaborative
crosstalk between myogenic and mesenchymal/endomy-
sial cells, enabling transcription of ColV in muscle con-
nective tissue [26-28].
The a1(VI), a2(VI) and a3(VI) chains assemble intra-
cellularly as monomers (1:1:1 ratio), from their C-term-
inal ends, and subsequently form dimers (two anti-
parallel, overlapping monomers) and tetramers (four
monomers) that are stabilized by disulfide bonds
between cysteine residues of the three chains [29-34].
ColVI chains are subjected to extensive post-transla-
tional modifications such as hydroxylation of lysine and
proline residues [35], and glycosylation of hydroxyly-
sines, which have been shown to be essential for the tet-
ramerization and further secretion of ColVI [36,37].
Upon secretion, tetramers are further aligned end to
end as microfibrils in the extracellular space, with a
characteristic beaded appearance [33] (Figure 1). To
date, somewhat contradictory results have been obtained
regarding the possible assembly of the newly character-
ized a(VI) polypeptides with the a1(VI), a2(VI) chains.
In transfection experiments, only a4(VI) appeared to
have this ability [19], whereas in mouse muscle, all three
were reported to do so [20]. Whether and how these
additional chains may fit in the pathogenesis of ColVI
myopathies remains unresolved to date, and needs to be
addressed more comprehensively. To date, in our cohort
of patients, no pathogenic mutations have been found
by sequencing of the COL6A5 and COL6A6 genes in
patients without mutations in the COL6A1-3 genes (V.
Allamand, data not shown).
Clinical phenotypes of collagen VI myopathies
The etiological definition of ColVI myopathies as a spe-
cific condition has evolved over the years with the blur-
ring of boundaries between two disorders, initially
described separately but now recognized as the extreme
ends of a continuous clinical spectrum [38,39] (Figure
2). The severe endpoint of this spectrum corresponds to
Ullrich congenital muscular dystrophy (UCMD, OMIM
254090; http://www.ncbi.nlm.nih.gov/omim), described
in 1930 as ‘congenital atonic-sclerotic muscular dystro-
phy’, emphasizing its early onset and the presence of
proximal joint contractures associated with a striking
distal hyperlaxity [40,41]. Orthopedic deformities (joint
contractures, scoliosis) and respiratory impairment with
diaphragmatic failure generally develop within the first
decade of life, and may be life-threatening. Arrest of
motor milestones with no acquisition of walking ability
is seen in a subset of patients, but most children are
able to walk, and show later progression of muscle
weakness with loss of ambulation around 10 years of
age, and a requirement for mechanical ventilation in late
childhood or young adulthood [42,43].
At the other end of the spectrum is the milder form
Bethlem myopathy (BM, OMIM 158810), described in
1976, which begins in the first or second decade,
although a neonatal history may be recognized, charac-
terized by early contractures of finger flexors, wrist,
elbows and ankles [44,45]. Respiratory failure and distal
hyperlaxity are usually absent or are milder than in
UCMD, although the latter may not be so uncommon
in very young children with BM. The course is usually
slow, with most of the patients remaining ambulatory.
However, progression of muscle weakness occurs often
in the fifth decade, resulting in about 50% of patients
requiring walking aids or a wheelchair [46]. Intermediate
phenotypes have been described, and named ‘mild
UCMD’ or ‘severe BM’, thereby reinforcing the notion
of clinical overlap between Ullrich and Bethlem pheno-
types [38,39].
Skin features such as follicular hyperkeratosis and
hypertrophic scars or keloid formation are common
[38,39,42,43,47-49]. Other common findings include
normal cognitive abilities, normal or only slightly raised
serum creatine kinase (CK) levels, and absence of car-
diac phenotype. Two other conditions that fall within
the spectrum of ColVI myopathies have been documen-
ted: autosomal dominant limb-girdle muscular dystro-
phy (LGMD) (in three families) and, more recently,
autosomal recessive myosclerosis myopathy (OMIM
255600) (in one family) [50,51].
The prevalences of UCMD and BM in northern Eng-
land has recently been reported as 0.13 and 0.77 per
100,000, respectively, amounting collectively to 0.9 per
100,000 [52]. UCMD seems to be the second most com-
mon type of congenital muscular dystrophy (CMD) in
Europe (behind laminin a2 chain deficiency; OMIM
607855) and also in Japan (behind Fukuyama congenital
muscular dystrophy; OMIM 253800, [53]) and Australia
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(behind a-dystroglycan glycosylation defects; [54]). In
the cohort from northern England, BM emerges as the
fourth most common myopathy behind myotonic dys-
trophy (OMIM 160900), facio-scapulo-humeral muscu-
lar dystrophy (OMIM 158900) and Duchenne/Becker
muscular dystrophy (OMIM 310200 and 300376) [52].
Differential diagnosis of ColVI-related myopathies
With the most prominent clinical presentation of
ColVI myopathies being muscle weakness and contrac-
tures, associated with variable degrees of hyperlaxity,
an important difficulty lies in defining boundaries and
contiguities, with the possible differential diagnosis
including congenital myopathies, Emery-Dreifuss mus-
cular dystrophy (EDMD; OMIM 181350), LGMD, rigid
spine muscular dystrophies, and other diseases of con-
nective tissues such as Ehlers-Danlos syndrome
[55-57]. Imaging techniques, such as computed
tomography or magnetic resonance imaging (MRI) of
muscle, are now recognized as very helpful in the diag-
nostic approach of muscle disease, because there are
specific patterns of muscle involvement in each of
these contractile myopathies as reported for EDMD
with LMNA mutations [58], muscular dystrophies with
rigidity of the spine [59], and ColVI myopathies
[58,60,61]. From these studies, the typical pattern of
muscle involvement in ColVI myopathies is now con-
sidered to be constituted by a diffuse, concentric hypo-
density of the thigh muscles with relative sparing of
the sartorius, gracilis and adductor longus muscles.
The vasti muscles are the most affected muscles. In
addition, a peculiar central area of abnormal signal is
seen within the rectus femoris, initially referred to as a
‘central shadow’ [62].
Figure 2 Clinical spectrum, associated spine deformation and muscle MRI in collagen type VI (ColVI) myopathies. (A), Early severe
phenotypes, corresponding to classic Ullrich congenital muscular dystrophy (UCMD), (B) intermediate forms seen in children or adults and (C)
less severe, classic Bethlem myopathy (BM) forms constitute the overlapping clinical presentations of ColVI myopathies. (D) Radiography showing
the evolution of spine deformation in a patient presenting with a classic early-onset UCMD phenotype. T1 transverse section of Bethlem
myopathy upper limb girdle (E) and (F) thighs. Note the fatty infiltration, which appears as hyperintense area on T1-weighted images, located
around the triceps brachialis muscles in (E) and along the fascia of vastus lateralis and vastus medialis muscles in (F) (yellow arrows). (G) The
concentric fatty involvement of the thigh muscles is also seen on whole body MRI. (Images courtesy of Drs Susana Quijano-Roy and Tanya
Stojkovic).
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In the context of the differential diagnosis, the absence
of raised CK levels, the lack of a cardiac phenotype, and
the presence of a specific MRI pattern are strongly sug-
gestive of a ColVI myopathy.
Molecular diagnosis and genetics
In light of the clinical variability and the overlapping
presentation with other muscular disorders, a definite
diagnosis can only be made after the identification of
pathogenic mutations in one of the COL6A genes,
which to date are restricted to COL6A1, COL6A2 and
COL6A3. However, the large size (106 coding exons in
total corresponding to 150 kb of genomic DNA) of
these genes makes routine molecular diagnostics costly
and time-consuming. The road to this ‘holy grail’ of
diagnosis is thus often lengthy and full of pitfalls, and
relies on a combination of clinical, biochemical and
molecular findings.
Historically, muscle biopsies were the routine and pri-
mary step undertaken for diagnostic purposes, and dou-
ble immunostaining with a basement-membrane marker
enabled recognition of ColVI deficiency in patients with
UCMD [63], but not in patients with BM. The current
diagnostic method of determining ColVI involvement is
primarily based on immunocytochemistry of cultured
skin fibroblasts, but this analysis is only available in a
limited number of laboratories to date. A number of
antibodies recognizing human ColVI are now commer-
cially available and may be used for such techniques; in
particular, the refined protocol proposed by Hicks et al.
[64], using a polyclonal antibody raised against mature
ColVI from human placenta, has better sensitivity, espe-
cially in fibroblast cultures from patients with BM
(Figure 3). The absence or alteration of ColVI secretion
in cultured fibroblasts, associated with clinical symptoms
compatible with a diagnosis of ColVI myopathy, cer-
tainly warrants further genetic analysis.
Over the past decade, the development of genetic stu-
dies has demonstrated the heterogeneity and complexity
of the molecular mechanisms at play in ColVI myopa-
thies. An autosomal recessive pattern of inheritance was
initially thought to be involved in UCMD, and linkage
analysis led to the identification of mutations in the
COL6A2 and COL6A3 genes [65-67]. However, numer-
ous dominant de novo mutations have now been shown
to be involved, accounting for more than 50% of the
mutations causing UCMD [38,39,42,68]. Similarly, auto-
somal dominant mutations were first identified in the
COL6A1 and COL6A2 genes in families with BM, sug-
gesting that BM was mostly familial and inherited as an
autosomal dominant disease [69], although rare de novo
mutations and autosomal recessive mutations have now
been reported [70-73]. To date, over 200 mutations
have been identified in these genes, mostly distributed
in the COL6A1 and COL6A2 genes. The most common
types of mutations are point mutations, and mutations
leading to premature termination codons (PTCs) and
exon skipping (Figure 4). Among the former, missense
changes affecting glycine residues in the triple helical
domains of the corresponding proteins are the most
common, and are often dominant de novo. Because
these changes affect crucial amino acids within the col-
lagenous domains, they hamper triple-helix formation
[74-77]. Splice mutations resulting in in-frame exon
skipping are generally dominant de novo mutations, and
exons 16 of COL6A3 and 14 of COL6A1 seem to be
preferentially affected, leading to UCMD or BM pheno-
types, respectively [53,75,78-83]. Nonsense mutations
and small deletions or insertions inducing PTCs within
the coding frame are mostly inherited as recessive muta-
tions, and lead to loss of function of the protein
[42,53,68,75,76,79-92]. These mutations are responsible
for most UCMD phenotypes. Nevertheless, it should be
noted that genotype-phenotype correlations are very dif-
ficult to identify.
It has recently been shown that all types of mutations
alter transcript levels, and that in the case of PTC-bear-
ing transcripts, which are specifically degraded via the
nonsense-mediated mRNA decay (NMD [93,94]) path-
way, quantification of the three COL6A mRNAs is a
helpful tool to pinpoint the mutated gene, thereby facili-
tating these cumbersome molecular analyses [42]. The
NMD-induced degradation of PTC-bearing transcripts
may also, at least in part, explain why the parents of
patients with UCMD who themselves harbor recessive
mutations are asymptomatic; their heterozygous status
sustains the expression of 50% of the ‘normal’ protein,
thereby leading to a ‘functional loss of heterozygosity’.
The study by Briñas and collaborators also provided
some genotype-phenotype correlations in a cohort of
patients with early-onset ColVI myopathy, showing that
recessive mutations leading to PTC were associated with
severe phenotypes [42]. Genetic studies are further com-
plicated by a possibly variable penetrance as reported by
Peat et al. [89].
Finally, the highly polymorphic nature of the COL6A
genes makes it difficult to definitely assign pathogenicity
to some variants, especially missense ones that do not
affect glycine residues within the triple-helix domains of
the proteins. In addition, these ‘polymorphisms’ may
very well play a role in the extreme clinical variability of
these conditions, particularly in patients carrying identi-
cal mutations but presenting with variable severity.
The types of mutations identified also reflect the
methods used in laboratories performing these analyses
(for example, sequencing of genomic DNA or of the
coding sequences on cDNA), but the emergence of
high-throughput methods (arrays) is likely to allow the
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identification of as yet unknown or under-recognized
pathogenic mechanisms, such as large gene rearrange-
ments, or promoter or deep intronic mutations, as
recently illustrated in two reports [95,96].
Animal models and pathophysiology
Limited access to muscle biopsies hinders extensive
investigations of the specific cellular mechanisms leading
to the development of the muscle pathology, and in
vitro/ex vivo cellular systems only partially reproduce
the complexity of the tissue. The development of the
first animal model of ColVI deficiency in 1998, engi-
neered by invalidating the Col6a1 gene in mice, has
proven central to understanding the cellular pathways
involved in these diseases. Homozygous animals were
reported to develop a mild myopathic phenotype, and
were initially described as a model of BM [97]. Interest-
ingly, the diaphragm was the most affected muscle, with
signs of necrosis evidenced by uptake of Evan’s blue dye
[97]. Subsequently, a latent mitochondrial dysfunction
accompanied by ultrastructural alterations of mitochon-
dria and the sarcoplasmic reticulum, resulting in sponta-
neous apoptosis, was found in about one-third of muscle
fibers [98]. Reduced contractile strength of the dia-
phragm and other muscle groups was also reported in
Col6a1
-/- mice in this initial study [98]. The maximal
Figure 3 Collagen type VI (ColVI) expression study in cultured skin fibroblasts. (A) Representative images obtained using the protocol
from [67] in which ColVI (red) is labeled with monoclonal antibody MAB1944 (Chemicon (now Millipore), Billerica, MA, USA) and perlecan (green)
with monoclonal antibody MAB1948 (Chemicon). Note that ColVI expression appeared clearly altered in a patient with an early severe (ES) form
and less so in patients with intermediate (Int) or Bethlem myopathy (BM) forms, compared with control fibroblasts (Cont). (B) Using the protocol
of Hicks et al. [64], which detects ColVI (red) with polyclonal antibody Ab6588 (Abcam, Cambridge, UK) and fibronectin (green) with monoclonal
antibody F15 (Sigma Chemical Co., St Louis, MO, USA), the sensitivity of the method is increased, and defective ColVI secretion could be
detected in all patients’ samples. Insets indicate nuclei, labeled using DAPI. Bars are 50 μm. (Images courtesy of Corine Gartioux and Valérie
Allamand).
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isometric tension generated by ColVI-deficient skinned
fibers from gastrocnemius was found to be reduced in a
recent report; however, using a protocol of eccentric
contractions in vivo, no muscle force drop was found,
indicating that the lack of ColVI does not impair myofi-
brillar function [99]. Importantly, mitochondrial dys-
function was also reported in cultured muscle cells from
patients and could be reversed by cyclosporin (Cs)A, an
immunosuppressive drug that prevents the opening of
the mitochondrial permeability transition pore through
binding to cyclophilin D, and also inhibits the phospha-
tase calcineurin [100,101]. Another in vitro study
showed that patients-derived skin fibroblasts behave dif-
ferently from myoblasts in that respect, and also ques-
tioned the specificity of this mitochondrial dysfunction
[102], warranting further studies on the matter.
A role for cell survival had previously been proposed
for ColVI because it was shown to prevent anti-a1
integrin-mediated apoptosis and trigger the downregula-
tion of bax, a pro-apoptotic molecule [103,104].
Recently, a study of the autophagic process in muscles
of Col6a1 knockout mice revealed that autophagy was
not induced efficiently [105]. The ensuing defective
autophagy provides the link between the previously
Figure 4 Repartition of the various types of mutations identified in the COL6A1, COL6A2 and COL6A3 genes. This schematic reflects, to
the best of our ability, the distribution of 258 allelic mutations (98 on COL6A1, 113 on COL6A2 and 47 on COL6A3). Dominant de novo mutations
represent 67% of the missense mutations, affecting glycine residues in the TH domains (Gly in TH), 57% of small deletions (< 5 amino acids) and
44% of splice-site mutations leading to in-frame exon skipping, whereas 97% of mutations leading to premature termination codons (PTCs) are
familial (recessive or dominant).
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Figure 5 Current pathological hypotheses and therapeutic targets. The currently known cascade of main events leading to myofiber
degeneration in ColVI-deficient skeletal muscle is shown. Mitochondrial dysfunction (due in part to the defective permeability transition pore
(PTP) opening) triggers an energetic imbalance with the increased levels of phosphorylated adenosine monophosphate-activated protein kinase
(p-AMPK), Ca2+ overload and the production of reactive oxygen species (ROS). Lack of autophagy induction exacerbates the cellular dysfunction
because defective mitochondria and proteins (such as p62 aggregates) are not cleared from the cytoplasm. Together, these defects lead to
increased apoptosis. Potential therapeutic interventions are indicated in green.
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described mitochondrial dysfunction and myofiber
degeneration, as abnormal organelles and molecules
cannot be efficiently cleared from the cell. This study
further showed that the forced induction of autophagy,
either by dietary restriction or by treatment with rapa-
mycin or CsA, ameliorated the phenotype of the
Col6a1
-/- mice (Figure 5). A similar alteration of autop-
hagy was also detected in muscle biopsies derived from
nine patients with UCMD or BM [105]. These data thus
provide a basis for novel therapeutic targets to promote
the elimination of defective organelles in ColVI-deficient
skeletal muscle.
Morpholino-mediated knock-down of the col6a1 and
col6a3 genes in zebrafish embryos showed that collagen
VI deficiency significantly impairs muscle development
and function [106]. Increased apoptosis, partially pre-
vented by CsA treatment, was also described in the zeb-
rafish morphants [106]. As in other instances,
perturbation of muscle components leads to a more
severe phenotype in zebrafish than in mouse models,
which may in part be due to intrinsic differences in
muscle development in these species, especially in terms
of timing. Zebrafish models have emerged as major in
vivo models of neuromuscular disorders, and seem to be
particularly well suited for whole-organism screens for
potential pharmacological treatments, as recently illu-
strated in zebrafish models of Duchenne muscular dys-
trophy [107].
Therapeutic intervention
To date, no curative treatment exists for these disorders,
and most patients rely on supportive treatment of symp-
toms, usually involving orthopedic (spinal deformations,
contractures) and respiratory complications [108].
The unveiling of mitochondrial dysfunction led to an
open pilot trial in five patients with UCMD or BM trea-
ted orally with CsA for 1 month [109]. This study
reported normalization of the mitochondrial dysfunction
and decrease of apoptosis of muscle cells following this
short-term treatment [110,111]. Longer treatment (up to
2 years) had some beneficial effect on muscle function
in these patients but did not prevent progression of the
disease in the children [38]. Debio-025 (D-MeAla3Et-
Val4-cyclosporin; DebioPharm) prevents the inappropri-
ate opening of the mitochondrial permeability transition
pore (PTP) without interfering with calcineurin [112],
and was shown to restore mitochondrial function in cul-
tured muscle cells of patients [100] and in Col6a1-/-
mice [113]. Debio-025 is currently being tested in a
phase II clinical trial in patients with chronic hepatitis
C. Another anti-apoptotic pharmacological agent that is
being investigated in the context of ColVI myopathies is
Omigapil (N-(dibenz(b, f)oxepin-10-ylmethyl)-N-methyl-
N-prop-2-ynylamine maleate; Santhera Pharmaceuticals),
a chemical derivative of (-)-deprenyl, which was shown
to reduce GAPDH-Siah1-mediated apoptosis in a mouse
model of laminin a2 chain deficiency [114].
It should be noted that translating some of this
research from animal models to patients represents a
challenging task, particularly because, to date, these
drugs have not been approved for use in children, the
patient population with the most severe forms of ColVI
myopathies. In addition, there is concern about these
therapeutic approaches because of the pleiotropic, and
potentially harmful, consequences of anti-apoptotic and/
or pro-autophagy treatments. Furthermore, such
approaches aiming at modulating downstream pathways
would not address the primary defect in these disorders,
that is, lack of ColVI in the connective tissue, and
would thus need to be continually administered. For the
sake of discussion, several alternative, and not necessa-
rily exclusive, therapeutic avenues that would sustain re-
expression of ColVI may be envisioned. These
approaches may consist of gene-based therapies, such as
vector delivery of ColVI-coding sequence, and antisense
inhibition of mutant transcripts exerting dominant-
negative effects [96]. Additionally, as nonsense muta-
tions leading to PTCs are often associated with early-
onset, severe phenotypes [42], pharmacological
approaches aiming to ‘force’ translation of PTCs (a phe-
nomenon known as ‘translational readthrough’ [115])
may prove beneficial for a subset of patients carrying
these types of mutations. However, the complex assem-
bly process and regulation of ColVI may prove challen-
ging and may limit the realistic options to be
investigated.
Conclusions
The past decade of research on neuromuscular disorders
has proven very exciting, and has seen ColVI myopa-
thies emerge as an important set of disorders, rather
under-recognized until recently. Many challenges remain
despite the tremendous advances in the understanding
of their genetic, biochemical and pathophysiological
bases. It is hoped that the decade(s) to come will see the
development of safe and efficient therapies for these dis-
orders. Consequently, as for other rare diseases, the
scientific community, and patient organizations, and
patients and their families have become increasingly
aware of the need for databases, both clinical and
genetic, to facilitate recruitment of patients for upcom-
ing clinical trials.
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